Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 6, 2026; 14(4): 117573
Published online Feb 6, 2026. doi: 10.12998/wjcc.v14.i4.117573
Published online Feb 6, 2026. doi: 10.12998/wjcc.v14.i4.117573
Mixed hepatocellular-cholestatic liver injury from cefepime: A case report
Reicelle Garcia, Department of Internal Medicine, Creighton University Medical Center - Bergan Mercy, Omaha, NE 68124, United States
Kevan English, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, United States
Co-first authors: Reicelle Garcia and Kevan English.
Author contributions: Garcia R and English K wrote the original draft, contributed to conceptualization, writing, reviewing, and editing; the authors read and approved the final version of the manuscript.
Informed consent statement: Written informed consent was obtained from the patient regarding the publication of this article and the associated image.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kevan English, MD, Department of Internal Medicine, University of Nebraska Medical Center, 42nd and Emile Street, Omaha, NE 68198, United States.
Received: December 11, 2025
Revised: December 29, 2025
Accepted: January 23, 2026
Published online: February 6, 2026
Processing time: 57 Days and 2.7 Hours
Revised: December 29, 2025
Accepted: January 23, 2026
Published online: February 6, 2026
Processing time: 57 Days and 2.7 Hours
Core Tip
Core Tip: Cefepime is a fourth-generation cephalosporin commonly used to treat various bacterial infections. It is safe and generally well-tolerated. While frequently associated with adverse effects such as neurotoxicity and nephrotoxicity, cases of hepatotoxicity are rare. Prompt cessation of the medication is the primary approach in management.